Novartis– tag –
-
Isomorphic Labs Secures $2.9 Billion in Partnerships with Eli Lilly and Novartis, Validating AI Drug Discovery Platform
GeneOnline Taiwan Overview Isomorphic Labs, a Google DeepMind spin-out, has solidified its AI drug discovery platform's value through significant partnerships totaling $2.9 billion with Eli Lilly ($1.7B) and Novartis ($1.2B). Concurrentl... -
Novartis Reverses ADC Holdout with $1.5B Myricx Deal Amid Sustained M&A Boom in ADC Market
Fierce Biotech USA Overview Novartis, previously hesitant about Antibody-Drug Conjugates (ADCs), has committed up to $1.5 billion to Myricx Bio, signaling a strategic shift into the burgeoning ADC market. This move follows a series of hi... -
Chai Discovery Raises $400M in Series C, Valuation Reaches $3.8B, Announces Novartis Collaboration
AIPressRoom USA Overview Chai Discovery has raised $400 million in a Series C round, bringing the AI drug discovery company's valuation to $3.8 billion. The company, which uses generative AI to design new antibodies and proteins, announc... -
EU Approves Itvisma: Single-Dose Gene Therapy Redefines SMA Treatment for Broad Patient Population Aged 2+
BioSpace (via Novartis press release) Europe Overview Novartis' gene therapy Itvisma® (onasemnogene abeparvovec) has received European Commission approval for children, adolescents, and adults aged 2 years and older with 5q spinal muscul... -
Antares and Novartis Forge $1.9B Deal to Tackle ‘Undruggable’ Cancer Targets with Small Molecules
Business Wire USA Overview Antares Therapeutics and Novartis have announced a strategic collaboration to discover, develop, and commercialize first-in-class small molecule therapies for previously 'undruggable' cancer targets. The agreem... -
Novartis’ Acquired RNA Therapeutic del-brax Achieves Phase 1/2 Success for Muscle-Wasting Diseases
BioPharma Dive USA Overview Novartis' RNA therapeutic del-brax, acquired through its $12 billion purchase of Avidity Pharmaceuticals, successfully completed a Phase 1/2 clinical trial for muscle-wasting diseases, achieving its primary en... -
Novartis and Orionis Biosciences Enter Strategic Collaboration for Molecular Glue Discovery in Up to $1.4 Billion Deal
BioBucks Biotech BD&L Tracker USA Overview Novartis announced a strategic collaboration with Orionis Biosciences to leverage Orionis' AI-driven "Allo-Glue™" platform across multiple challenging therapeutic targets. The deal includes a $4... -
U.S. Small Molecule API Market Forecast to Reach USD 103.37 Billion by 2035, Driven by HPAPI and Domestic Manufacturing
Precedence Research USA Overview This article presents an overview of a market research report published by Precedence Research, which projects the U.S. small molecule API market to reach USD 103.37 billion by 2035. Key growth drivers in... -
Isomorphic Labs Secures $2.1 Billion for AI Drug Discovery, Scaling AlphaFold-Driven Platform for Diverse Modalities
Pharmaceutical Technology UK Overview Isomorphic Labs, an Alphabet-backed AI drug discovery company, has closed a monumental $2.1 billion Series B funding round to accelerate its AI-driven drug development efforts. The investment will pr...
12